Jazz Pharmaceuticals secured the FDA's priority review for a long-delayed rare disease treatment, accelerating the path of a drug acquired in a $1 billion buyout.
We've heard plenty of anecdotal reports about expensive drugs, from the long-running brouhaha over Gilead Sciences' hepatitis C drugs to the consternation about pricey new cancer meds. But occasionally, there's a broader view--and not surprisingly, that shows some impressive price inflation, too.
South Korea's SK Biopharmaceuticals announced Phase III clinical trials of a medication for sleep disorders that will be led abroad by partner U.S.-based Jazz Pharmaceuticals, the Korea Herald said.
Jazz Pharmaceuticals has kicked off a rolling FDA submission for defibrotide, a rare disease treatment acquired in its $1 billion buyout of Gentium.
Forget Salix Pharmaceuticals and long-gone Shire. No. 1 on Allergan's list of defensive acquisition prospects could be Ireland's Jazz Pharmaceuticals.
Margins, margins, margins. That's an inevitable mantra among top investors and analysts. Just ask Novartis CEO Joe Jimenez, who's pledged big improvements in the Swiss drugmaker's spread. Or Eli Lilly CFO Derica Rice, who's had to explain why his company can promise to maintain margins as its sales spiral downward.
When Jazz Pharmaceuticals bought out the rare-disease drug developer Gentium for a billion dollars late last year, the company picked up a new therapy for severe veno-occlusive disease that it went on to launch in Europe last April. Now it's buying back the U.S. rights to the drug--which Gentium had bargained away to Sigma-Tau--for $75 million in cash and up to $175 million in milestones. And that extra cash will be staked entirely on its ability to shove the long-delayed drug through the FDA approval process.
Thanks to a steady flow of expensive new cancer therapies--and a public brouhaha over the cost of next-gen treatments for hepatitis C--drug prices are on center stage. We thought we'd look into the products whose prices have increased the most since 2007, to see how and why their prices are leaping.
Ireland's Jazz Pharmaceuticals, which has been buying up some new drug assets, has decided it will spend some money on manufacturing as well. It is building its first manufacturing facility there, adding to a string of plant projects in that country.
As Jazz Pharmaceuticals rolls on with an orphan drug deal spree, shareholders of Gentium, its latest target, are suing to stop the acquisition, saying the Irish company's $1 billion offer is far too low.